Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07681908 · ClinicalTrials.gov registry record · NA
#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys
A NA study, sponsored by Center for Innovative Public Health Research.
- Not yet
- Registry status
- NA
- Development phase
- 467
- Enrollment target
NCT07681908: Clinical Trial NA study, sponsored by Center for Innovative Public Health Research.
NCT07681908 is a NA study that has not yet begun recruiting, run by Center for Innovative Public Health Research. The registered enrollment target is 467 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07681908, a NA study, has not yet begun recruiting, sponsored by Center for Innovative Public Health Research.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 467 participants
- Enrollment target
Study Summary
Transgender and gender-diverse young people who were assigned female at birth (AFAB), including transgender boys, nonbinary youth, and others, face real sexual health disparities. Existing pregnancy and HIV prevention programs are designed for cisgender girls and do not meet the needs of AFAB trans youth, leaving this group without programs that speak to their lives. #TranscendentHealth is a text messaging sexual health program developed specifically for AFAB transgender and gender-diverse youth ages 14 to 18. It builds on Girl2Girl, a program shown to improve sexual health behaviors in LGB+ cisgender girls, and updates the content to reflect the identities, relationships, and health needs of AFAB trans youth. The study has two parts. In the first part, AFAB trans youth help shape the program through focus groups, Content Advisory Teams (youth review panels that give feedback on program messages), and a small pilot test. In the second part, a national randomized controlled trial enrolls 467 AFAB transgender youth ages 14 to 18 across the United States. Participants are randomly assigned to receive either #TranscendentHealth or a general sexual health text messaging program. Both programs are delivered entirely by text message over 5 months, with no in-person visits required. Youth complete short online surveys at the start of the program, at program end (5 months), and at 3 and 6 months after the program ends. The study's main goals are to determine whether #TranscendentHealth improves rates of condom-protected sex, use of other birth control methods (such as the pill, shot, or IUD), and HIV/STI testing. Secondary goals include reducing unintended pregnancy, increasing PrEP uptake among eligible participants, and improving intentions to use sexual health services.
Primary Outcome
The number of sex acts in the past 90 days divided by the number of sex acts in which a condom was used, assessed separately for penile-vaginal sex, penile-anal sex, sex with a sex toy and vagina, and sex with a sex toy and anus.
Interventions
- BEHAVIORAL #TranscendentHealth
- BEHAVIORAL Universal Sexual Health Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What is known before NCT07681908 opens enrollment
NCT07681908 is an interventional study that assigns participants to a tested intervention. The registered 467 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which #TranscendentHealth is the first listed.
NCT07681908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07681908 about?
NCT07681908 is a clinical study titled "#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys". Transgender and gender-diverse young people who were assigned female at birth (AFAB), including transgender boys, nonbinary youth, and others, face real sexual health disparities. Existing pregnancy and HIV prevention programs are designed for cisgender girls and do not meet the needs of AFAB trans ...
What is the current status of trial NCT07681908?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 467 participants. The study started on 2026-06-30. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07681908?
The interventions under investigation include: #TranscendentHealth (BEHAVIORAL), Universal Sexual Health Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT07681908?
This trial is sponsored by Center for Innovative Public Health Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07681908's enrollment target sits among peer trials
467 222nd of 2000 higher than 1,779 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI